Patents by Inventor Jacek Slon-Usakiewicz

Jacek Slon-Usakiewicz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110028719
    Abstract: The present invention relates to methods for screening, identifying, and/or quantifying modulators of amyloid and/or aggregates, fibrils or components thereof, in particular modulators of amyloid ?-peptide (A?) or A? fibrils. Aspects of the invention provide methods for screening putative modulators against an Amyloid target, in particular an A? target, so as to determine which modulators bind to or interact with the target, or interfere with the interaction of an indicator agent and the target. Particular aspects of the invention employ mass spectrometric methods for the screening of an Amyloid target against compound libraries, in particular mixtures of compounds or combinatorial libraries.
    Type: Application
    Filed: May 18, 2007
    Publication date: February 3, 2011
    Inventor: Jacek Slon-Usakiewicz
  • Patent number: 7041807
    Abstract: In general, the invention features antibodies specific for PrPSc and diagnostic, therapeutic, and decontamination uses thereof. The invention also features synthetic peptides useful as immunogens for generating antibodies specific for PrPSc and therapeutic for the treatment of prion diseases.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: May 9, 2006
    Assignee: Caprion Pharmaceuticals, Inc.
    Inventors: Neil R. Cashman, Eustache Paramithiotis, Jacek Slon-Usakiewicz, Ashkan Haghighat, Marc Pinard, Trebor Lawton
  • Patent number: 7041642
    Abstract: Light emitting compounds of the formula: where R1 is a light-emitting moiety, R2 is a bombesin-like peptide and fragment, derivative or analog thereof and L is a linker moiety, which may be present or absent. The peptide is linked at a first amino acid position to (C—X) which, in turn, is selected from the group including C?O, C?S, CH(OH), C?C=O, C?NH, CH2, CH(OR), CH(NR), CH(R), CR3R4, and C(OR3)OR4 where R, R3, and R4 are alkyl moieties or substituted alkyl moieties. Optionally the compound may include a linker moiety between the peptide and the C—X binding group. Preferably, the compound exhibits substantial biological activity in the presence of receptors having affinities for bombesin-like peptides.
    Type: Grant
    Filed: July 12, 1999
    Date of Patent: May 9, 2006
    Assignee: PerkinElmer LAS, Inc.
    Inventors: Clarissa Desjardins, Jacek Slon-Usakiewicz, Katherine J. Bonter
  • Patent number: 6680367
    Abstract: Light emitting compounds of the formula where R1 is a light-emitting moiety, R2 is a CRF-related peptide and fragment, derivative or analog thereof and L is a linker moiety, which may be present or absent. The peptide is linked at a first amino acid position to (C—X) which, in turn, is selected from the group including C═O, C═S, CH(OH), C═C═O, C═NH, CH2, CH(OR), CH(NR), CH(R), CR3R4, and C(OR3)OR4 where R, R3, and R4 are alkyl moieties or substituted alkyl moieties. Optionally the compound may include a linker moiety between the peptide and the C—X binding group. Preferably, the compound exhibits substantial biological activity in the presence of receptors having affinities for CRF-related peptides.
    Type: Grant
    Filed: July 19, 1999
    Date of Patent: January 20, 2004
    Assignee: Advanced Bioconcept Company
    Inventors: Clarissa Desjardins, Jacek Slon-Usakiewicz, Katherine J. Bonter
  • Patent number: 6677430
    Abstract: Light emitting compounds of the formula: where R1 is a light-emitting moiety and R2 is a motilin peptide and fragment, derivative or analog thereof The peptide is linked at a first amino acid position to (C—X) which, in turn, is selected from the group including C═O, C═S, CH(OH), C═C═O, C═NH, CH2, CH(OR), CH(NR), CH(R), CR3R4, and C(OR3)OR4 where R, R3, and R4 are alkyl moieties or substituted alkyl moieties. Optionally the compound may include a linker moiety between the peptide and the C—X binding group. Preferably, the compound exhibits substantial biological activity in the presence of receptors having affinities for motilin peptides.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: January 13, 2004
    Assignee: Advanced Bioconcept Company
    Inventors: Clarissa Desjardins, Jacek Slon-Usakiewicz, Katherine J. Bonter